<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>On AIDS Drugs, a Mixed Blessing</title>
    <meta content="LTR230107" name="slug"/>
    <meta content="22" name="publication_day_of_month"/>
    <meta content="5" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Monday" name="publication_day_of_week"/>
    <meta content="Editorial Desk" name="dsk"/>
    <meta content="18" name="print_page_number"/>
    <meta content="A" name="print_section"/>
    <meta content="4" name="print_column"/>
    <meta content="Opinion" name="online_sections"/>
    <docdata>
      <doc-id id-string="1201621"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Acquired Immune Deficiency Syndrome</classifier>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Prices (Fares, Fees and Rates)</classifier>
        <classifier class="indexing_service" type="descriptor">Vaccination and Immunization</classifier>
        <classifier class="indexing_service" type="descriptor">Third World and Developing Countries</classifier>
        <location class="indexing_service">Africa</location>
        <person class="indexing_service">Kerfoot, Matthew K</person>
        <classifier class="online_producer" type="types_of_material">Letter</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion/Letters</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Features/Travel/Guides/Destinations/Africa</classifier>
        <classifier class="online_producer" type="general_descriptor">Third World and Developing Countries</classifier>
        <classifier class="online_producer" type="general_descriptor">Acquired Immune Deficiency Syndrome</classifier>
        <classifier class="online_producer" type="general_descriptor">Acquired Immune Deficiency Syndrome</classifier>
        <classifier class="online_producer" type="general_descriptor">Vaccination and Immunization</classifier>
        <classifier class="online_producer" type="general_descriptor">Prices (Fares, Fees and Rates)</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Viruses</classifier>
        <classifier class="online_producer" type="general_descriptor">Diseases and Conditions</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
        <classifier class="online_producer" type="general_descriptor">Politics and Government</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000522T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9C05E1DC1E3AF931A15756C0A9669C8B63" item-length="157" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>On AIDS Drugs, a Mixed Blessing</hl1>
      </hedline>
      <abstract>
        <p>Letter from Matthew K Kerfoot says decision by pharmaceutical companies to lower cost of AIDS drugs may benefit Africans afflicted with that disease, but it does not bode well for long-term development of AIDS vaccine; says drug companies would be reluctant to develop product that would not return profit</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>To the Editor:</p>
        <p>The decision by five pharmaceutical companies to lower the cost of AIDS drugs may be beneficial for Africans afflicted by the disease, but this decision does not bode well for the long-term development of an AIDS vaccine (editorial, May 15).</p>
      </block>
      <block class="full_text">
        <p>To the Editor:</p>
        <p>The decision by five pharmaceutical companies to lower the cost of AIDS drugs may be beneficial for Africans afflicted by the disease, but this decision does not bode well for the long-term development of an AIDS vaccine (editorial, May 15).</p>
        <p>First, reduced revenues from the AIDS drugs will restrict research and development budgets. Second, a company that develops an AIDS vaccine will doubtless face tremendous pressure from AIDS activists, the medical community and world leaders to offer the vaccine at a reduced cost. Any company properly responsible to its shareholders will not focus resources toward the development of a product that will not return a profit.</p>
        <p>MATTHEW  K. KERFOOT  New York, May 15, 2000</p>
      </block>
    </body.content>
  </body>
</nitf>
